FY2025 EPS Estimate for OS Therapies Reduced by Analyst

OS Therapies Inc (NYSE:OSTX) – Equities research analysts at Brookline Capital Management reduced their FY2025 earnings estimates for shares of OS Therapies in a research note issued to investors on Wednesday, April 2nd. Brookline Capital Management analyst K. Raja now forecasts that the company will earn ($0.31) per share for the year, down from their previous forecast of ($0.22). The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share. Brookline Capital Management also issued estimates for OS Therapies’ FY2026 earnings at ($0.34) EPS.

A number of other equities analysts have also weighed in on the company. D. Boral Capital restated a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a research note on Monday. Lake Street Capital initiated coverage on shares of OS Therapies in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $19.00 price objective on the stock. Finally, Maxim Group raised their target price on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, OS Therapies has a consensus rating of “Buy” and an average target price of $18.00.

OS Therapies Stock Up 2.1 %

OS Therapies stock opened at $1.43 on Monday. OS Therapies has a fifty-two week low of $1.33 and a fifty-two week high of $7.00. The firm’s fifty day moving average price is $1.75 and its 200-day moving average price is $2.66.

Institutional Investors Weigh In On OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC increased its holdings in OS Therapies Inc (NYSE:OSTX) by 120.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 110,044 shares of the company’s stock after purchasing an additional 60,044 shares during the quarter. CM Management LLC owned 0.51% of OS Therapies worth $471,000 as of its most recent filing with the Securities & Exchange Commission.

Insider Buying and Selling at OS Therapies

In other OS Therapies news, major shareholder Shalom Auerbach sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $2.84, for a total value of $284,000.00. Following the completion of the sale, the insider now owns 2,431,211 shares of the company’s stock, valued at $6,904,639.24. This represents a 3.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 13.80% of the company’s stock.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.